We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

QUIDEL

Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App




FDA Clears Hand-Held Test for Bordetella Pertussis

By LabMedica International staff writers
Posted on 04 Jan 2015
The United States Food and Drug Administration (FDA) have cleared an accurate, easy-to-use molecular diagnostic assay for Bordetella Pertussis that employs a unique hand-held platform and requires no pre-extraction of DNA.

The incidence of whooping cough, the very contagious disease caused by B. More...
pertussis attaching to cilia that line part of the upper respiratory tract, has risen over the last few years. Whooping cough can cause serious illness in children and adults, and is most dangerous for infants and babies. Quidel Corporation (San Diego, CA, USA), a developer and provider of new diagnostic solutions, has received the FDA clearance for its AmpliVue Bordetella Assay to detect B. pertussis nucleic acids isolated from nasopharyngeal swab specimens obtained from patients suspected of having a respiratory tract infection attributable to B. pertussis.

AmpliVue Bordetella is an easy-to-use, self-contained, disposable molecular diagnostic test with superb clinical accuracy. The assay requires no upfront extraction of DNA and generates the result in approximately 75 minutes. The AmpliVue platform is based on Quidel’s novel Helicase Dependent Amplification (HDA) technology that enables rapid nucleic acid amplification without a thermal cycler. So, like all FDA-cleared AmpliVue assays, AmpliVue Bordetella is CLIA-classified as moderately complex and does not require investment in expensive thermocycling equipment. This benefit, plus less laboratory space requirements, can significantly lower cost when adopting new molecular testing methods.

"We are pleased to receive 510(k) clearance for our AmpliVue Bordetella Assay—our 5th assay in the AmpliVue format. We've shown that we can harness our proprietary HDA technology to develop fast, accurate molecular diagnostic assays with a menu that matters to our customers," said Douglas Bryant, president and CEO of Quidel, "Longer-term, we intend to leverage this technology for other molecular diagnostic applications that will be appealing to significant market segments and potentially to public health agencies worldwide."

Quidel's novel AmpliVue platform now enables laboratories of all sizes to perform highly sensitive and specific molecular tests, and currently has FDA clearance for B. Pertussis, C. difficile, Group A Strep, Group B Strep, HSV1 and HSV2.

Related Links:

Quidel Corporation



Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.